ACM
CRVS icon

ADAR1 Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

ADAR1 Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$80.3K – 223
2024
Q4 		$80.3K Buy
+15,000
New +$112K 0.02% 187

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ADAR1 Capital Management's CRVS Position: Q2 2026 in Review

ADAR1 Capital Management increased its Corvus Pharmaceuticals (CRVS) stake by 33% in Q2 2026, buying an estimated $405K and bringing the position to 117,101 shares worth $1.75M. The position accounts for 0.08% of the portfolio, ranked #145.

ADAR1 Capital Management first reported a position in CRVS in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.59M in Q4 2025. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • ADAR1 Capital Management held 117,101 shares of Corvus Pharmaceuticals worth $1.75M as of Q2 2026.
  • ADAR1 Capital Management bought 29,200 Corvus Pharmaceuticals shares in Q2 2026, an estimated $405K.
  • Corvus Pharmaceuticals made up 0.08% of ADAR1 Capital Management's portfolio in Q2 2026, its #145 holding.
  • ADAR1 Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • ADAR1 Capital Management's Corvus Pharmaceuticals position peaked at $3.59M in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.